Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Oct 15, 2025; 16(10): 110174
Published online Oct 15, 2025. doi: 10.4239/wjd.v16.i10.110174
Published online Oct 15, 2025. doi: 10.4239/wjd.v16.i10.110174
Association between antidiabetic drugs and cancer risk in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis
Xue-Dong An, Li-Yun Duan, Department of Endocrinology, Guang’anmen Hospital, Beijing 100053, China
Yue-Hong Zhang, Department of Endocrinology, Fangshan Hospital of Beijing University of Chinese Medicine, Beijing 102400, China
Qian-You Jia, Yan-Min Zhang, Department of Pediatrics, Rizhao Hospital of Traditional Chinese Medicine, Rizhao 276800, Shandong Province, China
Yun Qiao, Department of Traditional Chinese Medicine, Qilu Hospital of Shandong University, Jinan 250012, Shandong Province, China
Co-first authors: Xue-Dong An and Li-Yun Duan.
Author contributions: An XD and Duan LY wrote the first draft; An XD and Qiao Y conceived and designed the study; An XD, Jia QY, and Zhang YH analyzed the data; An XD, Duan LY, Zhang YH, Jia QY, Zhang YM, and Qiao Y were involved in data collection. An XD and Duan LY equally contributed to study design and manuscript writing. All authors interpreted the data and critically reviewed the manuscript.
Supported by National Natural Science Foundation of China, No. 82305205; Young Elite Scientists Sponsorship Program by China Association of Chinese Medicine, No. 2023-QNRC2-A05; Safeguard Project of Guang’anmen Hospital, China Academy of Chinese Medical Sciences, No. GAMHH9324001; and Special Program for the Training of Outstanding Young Scientific and Technological Talents Under the Basic Scientific Research Operating Expenses of the China Academy of Chinese Medical Sciences, No. ZZ18-YQ-011.
Conflict-of-interest statement: The authors report no relevant conflicts of interest for this article.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yun Qiao, PhD, Department of Traditional Chinese Medicine, Qilu Hospital of Shandong University, No. 107 Wenhua Xilu, Jinan 250012, Shandong Province, China. qiaoyun@qiluhospital.com.
Received: June 3, 2025
Revised: June 21, 2025
Accepted: August 22, 2025
Published online: October 15, 2025
Processing time: 138 Days and 3.7 Hours
Revised: June 21, 2025
Accepted: August 22, 2025
Published online: October 15, 2025
Processing time: 138 Days and 3.7 Hours
Core Tip
Core Tip: Diabetes has been linked to an increased risk of various cancers. Relevant research indicates that commonly used antidiabetic drugs have varying impacts on cancer risk; some provide protective effects, whereas others may increase the risk in specific populations. We conducted a network meta-analysis to compare the effects of different anti-diabetic drugs on the risk of various cancers in patients with type 2 diabetes mellitus.